Several studies demonstrated that the EWS::FLI1 fusion transcription factor plays a significant role in altering transcription in EWS cells [1], but data also suggest that other factors collaborate with EWS::FLI1 [26–30] leading to heterogeneous regulation of genes that support cancer plasticity and affect clinical presentation, therapeutic response, and patient outcomes. The gene discussed is FLI1; the disease is cancer.